Phylo partners with Ono Pharma as Biomni Lab raises a seed round led by a16z
KexinHuang5 · x · 2026-07-29
Phylo says it has partnered with Ono Pharma to deploy Biomni Lab to discovery scientists.
The product is positioned as an agentic AI platform for biomedical research, covering workflows from early discovery and target validation to hit-to-lead, lead optimization, and clinical analysis. The linked page also says Biomni Lab is being used by thousands of scientists and that the company has raised a seed round co-led by a16z and Menlo Ventures. The post frames agentic AI as a way to embed AI agents across the drug-discovery process and shorten hypothesis-to-analysis cycles.
More from Venture
- Fish Audio says its new voice model clones a speaker from 5 seconds of audio — JafarNajafov · 2026-07-29
- China’s venture market runs on “equity in name, debt in substance” and 2%–5% FA fees — deedydas · 2026-07-29
- An AI bubble debate turns on sample size, not just valuations, says a French press column — emmanuelvivier · 2026-07-29
- Bittensor’s $250M annual emissions are a tiny fraction of Big Tech’s AI spend — bittingthembits · 2026-07-29
- Indie Developer Criticizes Mailerlite's Pricing Model, Seeks Alternatives — JordanMorgan10 · 2026-07-29
- Indie Dev's AI Product Crosses $20K ARR — KevinNaughtonJr · 2026-07-29